Fulvestrant nanosphere/microsphere and preparative method and use thereof
Fulvestrant nanosphere/microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere/microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and/or spray drying method, and has the features of high drug loading and high encapsulation efficiency, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere/microsphere can be used to treat metastatic advanced breast cancer in post-menopausal woman.
1. A Fulvestrant microsphere, comprising:
a) fulvestrant or pharmaceutically acceptable salt or solvate thereof and
b) a methoxy ended polyethylene glycol-polylactic acid block copolymer,
wherein the particle size of the fulvestrant microsphere is between 10 μm and 1 mm, and
the fulvestrant microsphere comprises between 16.5% and 50% weight of fulvestrant or pharmaceutically acceptable salt or solvate thereof based on the amount of fulvestrant.
2. The fulvestrant microsphere according to claim 1 , wherein the methoxy ended polyethylene glycol-polylactic acid block copolymer is composed of hydrophilic fragment polyethylene glycol and lipophilic fragment polylactic acid.
3. A method of preparing for the fulvestrant microsphere according to claim 1 , wherein the method is in-liquid drying method.
4. The method according to claim 3 , wherein the in-liquid drying method includes the steps of:
a) dissolving the fulvestrant and the methoxy ended polyethylene glycol-polylactic acid block copolymer in the organic solvent to make an oil phase;
b) adding the oil phase in the aqueous phase and emulsifying to get the oil-in-water O/W type emulsion;
c) stirring and heating up the O/W type emulsion to completely volatilize the organic solvent in the O/W type emulsion;
d) filtering, washing, collecting and drying.
5. A pharmaceutical composition for treating breast cancer, comprising the fulvestrant microsphere according to claim 1 .
6. A method of treating breast cancer by administering to a patient in need thereof, a pharmaceutically acceptable effective amount of the fulvestrant microsphere according to claim 1 .
7. A method of treating breast cancer by administering to a patient in need thereof, a pharmaceutically acceptable effective amount of the fulvestrant pharmaceutical composition according to claim 5 .
8. The fulvestrant microsphere according to claim 1 , wherein the particle size of the fulvestrant microsphere is between 10 and 500 μm.
9. The fulvestrant microsphere according to claim 1 or claim 8 , wherein the fulvestrant microsphere comprises between 20% and 50% weight of fulvestrant or pharmaceutically acceptable salt or solvate thereof based on the amount of fulvestrant.
10. The fulvestrant microsphere according to claim 9 , wherein the fulvestrant microsphere comprises between 20% and 30% weight of fulvestrant or pharmaceutically acceptable salt or solvate thereof based on the amount of fulvestrant.
11. The fulvestrant microsphere according to claim 2 , wherein the structural formula of the methoxy ended polyethylene glycol-polylactic acid block copolymer is
wherein: m=4˜454, n=4˜2778.
12. The fulvestrant microsphere according to claim 11 , wherein m=between 11 and 227, n=between 70 and 2083.
13. The fulvestrant microsphere according to claim 12 , wherein m=between 22 and 113, n=between 139 and 1111.
14. The fulvestrant microsphere according to claim 2 , wherein the value of hydrophile-lipophile balance (HLB) of the methoxy ended polyethylene glycol-polylactic acid block copolymer is between 0.01 and 19.84.
15. The fulvestrant microsphere according to claim 14 , wherein the HLB value is between 0.4 and 12.0.
16. The fulvestrant microsphere according to claim 15 , wherein the HLB value is between 1.47 and 15.0.